Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Award - Doctoral Foreign Study Award (DFSA)

Direct Payment

$105,000.00

Characterization and Detection of Circulating Tumor DNA in Liquid Biopsy for Cancer

FY 2018-19

Summary
Lung cancer is the most common cause of cancer-related death in Canada and technologies to detect and monitor the disease are sorely needed. Currently, this is done through frequent tissue biopsy, but this is unpractical and challenging if the tumor is too small. Alternatively, cancer mutational targets can be found in the blood and saliva of cancer patients in a concept called liquid biopsy. Recently, the fragment lengths of circulating tumor DNA (ctDNA) has been shown to differ amongst cancer and healthy patients which can explain why current DNA detection technologies such as digital droplet PCR have difficulty finding tumor DNA in biofluids. Electric field-induced release and measurement (EFIRM) technology, however, can detect these tumor fragments accurately in plasma and saliva samples from lung cancer patients. We hypothesize that a combination of shorter circulating tumor DNA and EFIRM's mechanics may explain the detection performance in biofluids. This proposal has three fundamental goals to scientifically underpin the performance of EFIRM liquid biopsy. Firstly, we will isolate DNA from plasma and saliva samples from lung cancer patients to study various characteristics, one being length. Secondly, we will examine and describe how DNA capturing probe design and density impact EFIRM's ability to locate tumor DNA in biofluids. Thirdly, we will use EFIRM to demonstrate a proof of concept of liquid biopsy by measuring the changes of tumor DNA in the saliva and blood samples of lung cancer patients throughout their cancer treatment. The impact of this study is multi-factorial. Learning about tumor DNA characteristic will provide new biological information about these tumor biomarker targets. Understanding EFIRM fundamental mechanics will reveal the scientific rationale of its performance. Third, we will introduce a tool which can reliably monitor and adjust drug selection in patients undergoing cancer therapy.
Program
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Location
California, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
404185
Name
Cheng Jordan
Region
California
Country
United States of America
Orgtype
Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Characterization and Detection of Circulating Tumor DNA in Liquid Biopsy for Cancer
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award - Doctoral Foreign Study Award (DFSA)
Keyworddelim
Ctdna; Diagnostics; Liquid Biopsy; Non-Small Cell Lung Carcinoma; P.Exon19del; P.L858r; P.T790m
Abstract
Lung cancer is the most common cause of cancer-related death in Canada and technologies to detect and monitor the disease are sorely needed. Currently, this is done through frequent tissue biopsy, but this is unpractical and challenging if the tumor is too small. Alternatively, cancer mutational targets can be found in the blood and saliva of cancer patients in a concept called liquid biopsy. Recently, the fragment lengths of circulating tumor DNA (ctDNA) has been shown to differ amongst cancer and healthy patients which can explain why current DNA detection technologies such as digital droplet PCR have difficulty finding tumor DNA in biofluids. Electric field-induced release and measurement (EFIRM) technology, however, can detect these tumor fragments accurately in plasma and saliva samples from lung cancer patients. We hypothesize that a combination of shorter circulating tumor DNA and EFIRM's mechanics may explain the detection performance in biofluids. This proposal has three fundamental goals to scientifically underpin the performance of EFIRM liquid biopsy. Firstly, we will isolate DNA from plasma and saliva samples from lung cancer patients to study various characteristics, one being length. Secondly, we will examine and describe how DNA capturing probe design and density impact EFIRM's ability to locate tumor DNA in biofluids. Thirdly, we will use EFIRM to demonstrate a proof of concept of liquid biopsy by measuring the changes of tumor DNA in the saliva and blood samples of lung cancer patients throughout their cancer treatment. The impact of this study is multi-factorial. Learning about tumor DNA characteristic will provide new biological information about these tumor biomarker targets. Understanding EFIRM fundamental mechanics will reveal the scientific rationale of its performance. Third, we will introduce a tool which can reliably monitor and adjust drug selection in patients undergoing cancer therapy.
Competitiondate
201810
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Cheng, Jordan
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~
Direct Payment - $105,000 Grant (2018-19) | Canada Spends